Up 44.8%. 2012 Portfolio gain to date based on $218,620 valuation increase less $2,950 interest
Up 38.3%. 2012 Portfolio gain to date based on return on invested capital
Up 20.0%. 2012 Pfizer stock price gain to date including four 22-cent dividends
Up 13.7%. S & P 500 gain to date (1,258 to 1,430)
Note: This portfolio had a steady cost basis of $100,000 from 11/17/04 inception through 6/2/08. From that date through mid-March of 2009, additional funds were invested until the cost basis reached $296,110. The basis has remained steady again since that time.
Note: This portfolio was up by as much as 96K pre-crash on 6/1/07 with the stock closing at $27.68 that day. It was also down as much as 333K on 3/2/09 when the stock closed at $11.66. Gains of 429K from inception were seen on 12/18/12 with the stock at $25.64. Current gains are 404K.
Note: Over time, the leverage factor at these portfolio levels is about 1.9, the lowest since inception. It was designed at the end of 2011 to go up by about 59K per Pfizer point up to $25 on the stock and then 53K a point thereafter. .
Note: Average annualized gains from inception stands at 10.9% and considers all additional funds needed to margin the naked puts.